Clinical Trial Update: Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of ibrutinib with rituximab and lenalidomide in previously untreated stage II-IV follicular lymphoma or marginal zone l…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Ibrutinib (ibrutinib)
• Lenalidomide (lenalidomide)
• Rituximab (rituximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2024-09-24